Bank of New York Mellon Corp purchased a new position in Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) during the first quarter, Holdings Channel reports. The firm purchased 21,039 shares of the biotechnology company’s stock, valued at approximately $157,000.
Separately, Norges Bank acquired a new stake in Aeglea BioTherapeutics during the fourth quarter worth approximately $275,000. Hedge funds and other institutional investors own 31.52% of the company’s stock.
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) traded up 0.368% during midday trading on Friday, hitting $3.001. The stock had a trading volume of 491 shares. The company’s 50 day moving average price is $3.54 and its 200-day moving average price is $5.22. The stock’s market capitalization is $49.37 million. Aeglea BioTherapeutics, Inc. has a 52 week low of $2.85 and a 52 week high of $10.34.
Aeglea BioTherapeutics (NASDAQ:AGLE) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.47). The company had revenue of $0.98 million for the quarter. Aeglea BioTherapeutics had a negative return on equity of 39.19% and a negative net margin of 506.49%. Equities analysts anticipate that Aeglea BioTherapeutics, Inc. will post ($2.01) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/08/11/bank-of-new-york-mellon-corp-purchases-shares-of-21039-aeglea-biotherapeutics-inc-agle.html.
A number of research firms have recently commented on AGLE. Zacks Investment Research raised Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research report on Thursday, August 3rd. TheStreet lowered Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a research report on Friday, May 26th. Finally, ValuEngine raised Aeglea BioTherapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd.
Aeglea BioTherapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Want to see what other hedge funds are holding AGLE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE).
What are top analysts saying about Aeglea BioTherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aeglea BioTherapeutics Inc. and related companies.